15 January 2023 - Rykindo is a bi-weekly long-acting risperidone injection and is the first innovative therapy from Luye Pharma's central nervous system product portfolio to be marketed in the United States.

Luye Pharm today announced that the US FDA has approved Rykindo (risperidone) for extended-release injectable suspension for the treatment of schizophrenia in adults and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults.

Read Luye Pharma press release